The city of Ann Arbor, Michigan, currently has 8 active clinical trials seeking participants for Type 2 Diabetes research studies.
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
07/22/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Innovative Automated Insulin Delivery System for Type 2 Diabetes
Recruiting
The goal of this clinical trial is to learn if the twiist insulin delivery system works to treat adults with insulin-treated type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus
Renal Mechanism of SGLT2 Inhibition
Recruiting
Canagliflozin is an oral drug which is currently approved for use in patients with type 2 diabetes by the US Food and Drug Administration (FDA). Canagliflozin acts by increasing salt and sugar loss in the urine, and has shown to protect heart, kidney, and blood vessel function in patients with type 2 diabetes. However, it is unknown how canagliflozin protects the kidneys from disease. Therefore, this study plans to learn more about how canagliflozin works to protect against diabetic kidney disea... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/15/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Type 2 Diabetes, Diabetic Kidney Disease
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting
This research study collects health-related information and blood samples to better understand how body composition, lifestyle habits, and diet influence meta-inflammatory monocytes (MiMos) in adolescents. The hypothesis of this study is that adolescents at risk for metabolic disease have enhanced MiMo related activities leading to insulin resistance.
Gender:
ALL
Ages:
Between 14 years and 18 years
Trial Updated:
05/03/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Type 2 Diabetes, Insulin Resistance, Obesity, Metabolic Disease, PreDiabetes
Michigan Men's Diabetes Project III(MenDIII): Mind and Motion
Recruiting
The Michigan Men's Diabetes Project III: Mind \& Motion is an 7-month pilot randomized clinical trial. The investigators are looking to recruit 80 Black men with type 2 diabetes (T2D) (need to have diagnosis for at least one year) that are over the age of 18. Participants also must be under the care of a physician for their diabetes, self report an Hemoglobin A1c (A1C) of 7.0% or more in the last year, be willing to participate in study events (weekly physical activity, exercise and Cognitive Be... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Diabetes Mellitus, Type 2, Depressive Symptoms, Depression
The Breakfast Study
Recruiting
The investigators will conduct an acceptability, feasibility, preliminary effectiveness trial of a 4-month, online, very low-carbohydrate breakfast-focused program in 120 adults with type 2 diabetes. The investigators will measure acceptability and feasibility, plus critical efficacy outcomes, such as changes in HbA1c, anti-hyperglycemic medications, glycemic variability, body weight, blood pressure, and lipids.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/21/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Type 2 Diabetes
Mechanism of SGLT2 Inhibition in the Kidney
Recruiting
The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years. Participants will be asked to sign a consent and complete a screening visit prior to study entry including the following procedures for... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/01/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Type 2 Diabetes, Diabetic Kidney Disease
RESET System Pivotal Trial (Rev F)
Recruiting
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study. A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the RESET System plus moderate intensity lifestyle and dietary counseling compliant with 2024 ADA Standard of Care as compared to a sham control receiving moderate intensity lifestyle an... Read More
Gender:
ALL
Ages:
Between 22 years and 65 years
Trial Updated:
07/16/2024
Locations: Michigan Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, Michigan
Conditions: Diabetes type2, Obesity